Filter
1471
Text search:
Pharmaceutical
Assessment
Featured
140
371
Language
Document type
685
314
251
82
77
20
19
12
5
3
2
1
Countries
59
59
58
58
38
37
36
35
32
30
28
25
22
21
20
19
19
19
18
17
16
15
15
14
11
10
10
10
9
9
8
8
8
7
6
5
5
5
5
5
5
5
4
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
645
102
75
70
33
25
13
1
Toolboxes
151
132
130
88
62
47
39
37
28
27
25
24
23
23
19
19
18
11
9
8
5
5
3
1
1
Prevention Of Cardiovascular Disease: Guidelines For Assessment And Management Or Cardiocascular Risk
recommended
This publication provides guidance on reducing disability and premature deaths from coronary heart disease, cerebrovascular disease and peripheral vascular disease in people at high risk, who have not yet experienced a cardiovascular event.
WHO Pharmacovigilance indicators: a practical manual for the assessment of pharmacovigilance systems
This manual provides a practical method for determining the pharmacovigilance indices. It is designed to be simple and can be understood by any worker in pharmacovigilance without formal training in monitoring and evaluation. Pharmacovigilance as a medical discipline is crucial in preventing medicin
...
UNAIDS 2017 / Reference
Generating evidence for policy and action on HIV and social protection
This document provides guidance on the application of non-pharmaceutical countermeasures to minimise the spread of the 2019 novel coronavirus (2019-nCoV) in the population. Some of the measures proposed refer specifically to certain phases of the ep
...
Rwanda Guidelines for variation to registered pharmaceutical products.
Cardiovascular disease is a major cause of disability and premature death throughout the world, and contributes substantially to the escalating costs of health care. The underlying pathology is atherosclerosis, which develops over many years and is usually advanced by the time symptoms occur, genera
...
A tutorial for healthcare professionals
This guideline is intended to provide requirements to applicants wishing to submit
applications for registration of medicines in Botswana.
Lancet Planet Health 2020; 4: e271–79
This analysis focused on the chronic form of HAT caused by T. b. gambiense, as it contributes to the majority of disease burden. Information from the literature review,
product development landscape, and stakeholder interviews was compiled to:
- Identify use cases and understand current diagnosti
...
These guidelines have been developed to provide guidance to the Ministry of Health in managing applications for registration of human pharmaceutical products in Rwanda. It was compiled by the Technical Working Group (TWG) on Medicines Evaluation and
...
Compilation of country case studies and best practices. World Health Report (2010) Background Paper, 25
